Cell rejuvenation
Research programs studying cellular health and resilience.
SHARK MONEYYACHT CLUBSearch Shark Money
Search public and private companies, people, funds, markets, tools, and research.
Private markets
Health & Frontier Tech · Cellular Rejuvenation
Altos Labs
Researches cellular rejuvenation and approaches to reversing disease-related cell damage.
- Research status
- Research coverage
- Headquarters
- San Francisco, CA
- Coverage
- 2 product lines mapped
- Last reviewed
- September 2026
Product map
What the company builds
Products and operating platforms help connect company-level news to the revenue pools, customers, competitors, and supply chains it may affect.
Institute science
Integrated discovery, computation and translational research.
01 / THE BUSINESS
How Altos Labs creates value.
Researches cellular rejuvenation and approaches to reversing disease-related cell damage. The research focus is whether customer adoption can support attractive economics after development, delivery and ongoing service costs.
SectorHealth & Frontier Tech
Founder coverage1 profile
Research checkedSep 18, 2026
02 / PEOPLE BEHIND THE COMPANY
Meet the builders.
Co-founder
Rick Klausner
Rick Klausner is a co-founder of Altos Labs. The company’s founding and leadership material provides context for its work in cellular rejuvenation.
Explore founderSelected founders; historical founding roles are distinct from current management positions.
03 / CAPITAL & OWNERSHIP
Follow the financing.
Selected disclosed events, newest first. Announcement values describe that transaction and date; they are not current share prices. Debt, equity and secondary transactions are identified separately.
A financing figure is not established here.
Use the original company sources below to check new announcements. We have not substituted an estimate for a disclosed round.
04 / IN THEIR OWN WORDS
Watch. Listen. Form your view.
A direct interview has not yet been verified for this profile. The company’s official materials are linked below.
Interviews reflect the speaker’s perspective at publication. Company statements are not independent verification.
05 / EDITORIAL ANALYSIS
The opportunity. The open questions.
Our interpretation of the business model and cited sources, not a valuation or a recommendation.
The case to investigate
- Scientific validation of cellular programming and translation into human therapies.
- A stronger product position becomes economically meaningful when customers renew, expand and pay enough to cover delivery costs.
Pressure-test the thesis
- Very early science.
- Long clinical timelines.
- Uncertain commercial pathways.
What to watch next
01
Peer-reviewed findings — what changed in the latest original disclosure?
02
Clinical pipeline formation — what changed in the latest original disclosure?
03
Research talent — what changed in the latest original disclosure?
YOUR RESEARCH WORKSPACE
Keep the questions that matter.
Use this checklist to record what you have investigated. Your notes stay in this browser.
06 / RESEARCH TRAIL
Go straight to the source.
Research checked Sep 18, 2026. Selected public disclosures, not a complete capitalization table or securities-filing search. Missing information is left unconfirmed. No investment availability or IPO date is implied.
Scientific validation of cellular programming and translation into human therapies.
Private-company information is incomplete, episodic, and difficult to verify. Treat every data point as a starting point for diligence—not a substitute for company-approved materials, legal review, or investment analysis.
Add to my private currentSignals to monitor
Peer-reviewed findingsClinical pipeline formationResearch talentRisks to underwrite
Very early scienceLong clinical timelinesUncertain commercial pathways Underwriting map
What an investor should actually diligence
Map scientific evidence, regulatory pathway, clinical utility, reimbursement, manufacturing, and cash runway independently. Technical possibility is not the same as a financeable product path.
Buyer map
01
Patients and clinicians
02
Health systems
03
Payers
04
Research and strategic partners
Economics to request
01
Cash runway through next value inflection
02
Trial design and enrollment requirements
03
Manufacturing and quality-system cost
04
Expected pricing and reimbursement pathway
05
Licensing or partnership economics
Moat tests
01
Evidence is reproducible and clinically meaningful
02
Regulatory path is specific and funded
03
Manufacturing can meet required quality
04
Platform creates multiple credible programs
Milestone map
01
Preclinical or clinical readout
02
Regulatory clearance
03
Manufacturing validation
04
Strategic partnership
Comparable lensesMedical devicesBiotechnology platformsResearch toolsNeurotechnology
Underwriting framework
How to diligence Altos Labs
A company-specific starting point based on the operating realities of health & frontier tech. Replace assumptions with verified company materials, customer evidence, legal documents, and expert work.
Cash runway through the next clinical milestone
Trial cost and enrollment assumptions
Manufacturing and procedure economics
Reimbursement and addressable patient population
Peer-reviewed or independently reviewed evidence
Regulatory clearance to advance
Durable clinical outcomes
Manufacturing consistency and safety
Clinical-stage biotechnology
Medical devices
Research platforms
Approved standard of care
What is the next value-inflecting endpoint?
What evidence would stop the program?
Can results scale beyond a small cohort?
Who pays and how is adoption delivered?
No securities are offered here.
SMYC does not represent that shares are available, transferable, appropriately priced, or suitable for any person. Private securities are illiquid, speculative, subject to transfer restrictions, and may result in total loss.